NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $4.04 -0.01 (-0.12%) As of 03:36 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arbutus Biopharma Stock (NASDAQ:ABUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arbutus Biopharma alerts:Sign Up Key Stats Today's Range$3.97▼$4.0950-Day Range$3.65▼$5.1852-Week Range$3.50▼$5.45Volume1.10 million shsAverage Volume2.94 million shsMarket Capitalization$618.53 millionP/E Ratio3.57Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection. Its research programs include RNA interference (RNAi) therapies, immune-based treatments and capsid assembly inhibitors, which target different aspects of the virus and the body’s response to infection. The company’s investigational portfolio includes imdusiran, an RNAi therapeutic designed to reduce hepatitis B surface antigen, as well as other HBV drug candidates at various stages of development. Arbutus also develops drug-delivery technologies, including lipid nanoparticles and GalNAc-based approaches. Arbutus adopted its current name in 2015 following the merger of Tekmira Pharmaceuticals and OnCore Biopharma. The company’s research and development efforts remain centered on advancing potential therapies for people with chronic HBV infection.AI Generated. May Contain Errors. Read More Arbutus Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreABUS MarketRank™: 1.338457460905 of 5 starsArbutus Biopharma scored higher than 27% of companies evaluated by MarketBeat, and ranked 775th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingArbutus Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is 3.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is 3.57, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.24.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.53% of the float of Arbutus Biopharma has been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 9.14.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 19.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment1.20 News SentimentArbutus Biopharma has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.90% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABUS Stock News HeadlinesHead-To-Head Survey: Arbutus Biopharma (NASDAQ:ABUS) vs. BioMarin Pharmaceutical (NASDAQ:BMRN)November 17 at 3:13 AM | americanbankingnews.comArbutus Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 10, 2026 | globenewswire.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 17 at 1:00 AM | Profits Run (Ad)Arbutus Biopharma's AB-101 Gets FDA Hold Lifted In Hepatitis B ProgramOctober 22, 2026 | rttnews.comArbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B DrugOctober 22, 2026 | finance.yahoo.comArbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 InhibitorOctober 22, 2026 | globenewswire.comArbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV CureOctober 8, 2026 | seekingalpha.comArbutus Announces Final Results of Its US$230 Million Modified 'Dutch Auction' Tender OfferOctober 2, 2026 | marketscreener.comMSee More Headlines ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $4.81 on January 1st, 2026. Since then, ABUS stock has decreased by 16.3% and is now trading at $4.0250. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Corporation (NASDAQ:ABUS) posted its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.32. The biopharmaceutical company earned $299 thousand during the quarter, compared to analyst estimates of $1 million. Arbutus Biopharma had a net margin of 121.17% and a trailing twelve-month return on equity of 129.12%. Is Arbutus Biopharma buying back stock? Arbutus Biopharma's Board of Directors initiated a stock buyback program on Friday, August 21st 2026, which allows the company to repurchase outstanding shares, according to EventVestor. This allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its stock is undervalued. Who are Arbutus Biopharma's major shareholders? Top institutional shareholders of Arbutus Biopharma include Two Seas Capital LP (4.11%), State Street Corp (3.57%), Goldman Sachs Group Inc. (1.68%) and First Trust Advisors LP (0.35%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Tesla (TSLA), NIO (NIO), Sorrento Therapeutics (SRNE), Plug Power (PLUG), Moderna (MRNA), Inovio Pharmaceuticals (INO) and NVIDIA (NVDA). Company Calendar Last Earnings11/10/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, ABUS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABUS CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees19Year Founded2005Profitability EPS (Trailing Twelve Months)$1.13 Trailing P/E Ratio3.57 Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.50 million Net Margins121.17% Pretax Margin121.17% Return on Equity129.12% Return on Assets89.26% Debt Debt-to-Equity RatioN/A Current Ratio1.40 Quick Ratio81.42 Sales & Book Value Annual Sales$14.08 million Price / Sales43.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book7.21Miscellaneous Outstanding Shares153,290,000Free Float122,788,000Market Cap$618.53 million OptionableOptionable Beta0.84 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ABUS) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored“IMPERIUM”: The #1 investment of 2027Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A...Banyan Hill Publishing | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.